SI2448945T1 - Kristalinične oblike prasugrelovih soli - Google Patents

Kristalinične oblike prasugrelovih soli

Info

Publication number
SI2448945T1
SI2448945T1 SI201130445T SI201130445T SI2448945T1 SI 2448945 T1 SI2448945 T1 SI 2448945T1 SI 201130445 T SI201130445 T SI 201130445T SI 201130445 T SI201130445 T SI 201130445T SI 2448945 T1 SI2448945 T1 SI 2448945T1
Authority
SI
Slovenia
Prior art keywords
crystalline forms
prasugrel
salts
prasugrel salts
crystalline
Prior art date
Application number
SI201130445T
Other languages
English (en)
Inventor
Mihaela Tuksar
Tomislav Biljan
Miroslav Zegarac
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44065677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2448945(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of SI2448945T1 publication Critical patent/SI2448945T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SI201130445T 2010-04-08 2011-04-07 Kristalinične oblike prasugrelovih soli SI2448945T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US32216510P 2010-04-08 2010-04-08
US32688210P 2010-04-22 2010-04-22
US34891410P 2010-05-27 2010-05-27
US35530410P 2010-06-16 2010-06-16
PCT/US2011/031602 WO2011127300A1 (en) 2010-04-08 2011-04-07 Crystalline forms of prasugrel salts
EP11715144.9A EP2448945B1 (en) 2010-04-08 2011-04-07 Crystalline forms of prasugrel salts

Publications (1)

Publication Number Publication Date
SI2448945T1 true SI2448945T1 (sl) 2015-05-29

Family

ID=44065677

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130445T SI2448945T1 (sl) 2010-04-08 2011-04-07 Kristalinične oblike prasugrelovih soli

Country Status (11)

Country Link
US (2) US8802854B2 (sl)
EP (2) EP2883877A1 (sl)
JP (2) JP5730986B2 (sl)
KR (3) KR20120052381A (sl)
CN (1) CN102656175B (sl)
ES (1) ES2533681T3 (sl)
HR (1) HRP20150356T1 (sl)
PL (1) PL2448945T3 (sl)
PT (1) PT2448945E (sl)
SI (1) SI2448945T1 (sl)
WO (1) WO2011127300A1 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120052381A (ko) 2010-04-08 2012-05-23 테바 파마슈티컬 인더스트리즈 리미티드 프라수그렐 염의 결정형
CZ305314B6 (cs) * 2010-12-30 2015-07-29 Zentiva, K.S. Nový hydrobromid formy C 5-[2-cyklopropyl-1-(2-fluorofenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráněným názvem prasugrel a způsob jeho výroby
CN103173432B (zh) 2011-12-22 2020-08-04 通用电气公司 分离核酸的方法及装置
CN103012427B (zh) * 2012-11-26 2015-07-08 天津大学 一种普拉格雷盐酸盐乙醇溶剂化物及其制备方法
WO2016203018A1 (en) 2015-06-19 2016-12-22 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
CN107814810A (zh) * 2016-09-14 2018-03-20 天津科技大学 一种普拉格雷硫酸氢盐新晶型及其制备方法
CN107915743A (zh) * 2016-10-10 2018-04-17 天津科技大学 一种普拉格雷硫酸氢盐晶型iv及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
KR20090033917A (ko) 2000-07-06 2009-04-06 다이이찌 산쿄 가부시키가이샤 히드로피리딘 유도체 산부가염
TWI392681B (zh) 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
US20100204470A1 (en) 2006-06-27 2010-08-12 Sandoz Ag method for salt preparation
US20100261908A1 (en) 2007-11-09 2010-10-14 Dr. Reddy's Laboratories Ltd. Processes for the preparation of prasugrel , and its salts and polymorphs
WO2009066326A2 (en) 2007-11-19 2009-05-28 Msn Laboratories Limited Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
WO2009098142A1 (en) 2008-02-06 2009-08-13 Helm Ag Prasugrel salts with improved properties
CN101255169B (zh) 2008-03-26 2010-11-10 山东大学 普拉格雷盐及其制备方法
WO2009129983A1 (en) 2008-04-21 2009-10-29 Ratiopharm Gmbh Acid addition salts of prasugrel and pharmaceutical compositions comprising the same
ES2353853T3 (es) 2008-04-25 2011-03-07 Sandoz Ag SAL HIDROGENOSULFATO DE 2-ACETOXI-5-("ALFA"-CICLOPROPILCARBONIL-2-FLUORBENCIL)-4,5,6,7-TETRAHIDROTIENO[3,2-c]PIRIDINA Y SU PREPARACIÓN.
EP2325187A4 (en) 2008-08-02 2011-09-28 Lunan Pharm Group Corp PRASUGREL HYDROGENOSULFATE, ITS MEDICINAL COMPOUND AND USE THEREOF
WO2010070677A2 (en) 2008-12-15 2010-06-24 Glenmark Generics Limited A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
EP2398468B1 (en) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
RU2484094C1 (ru) * 2009-03-31 2013-06-10 Шанхай Инститьют Оф Фармасьютикал Индастри Кристаллы гидробромата прасугреля
GB2469883A (en) 2009-04-30 2010-11-03 Sandoz Ag Novel crystalline form of Prasugrel hydrogensulphate
EP2451816A4 (en) 2009-07-06 2013-02-27 Glenmark Generics Ltd CRYSTALLINE FORM OF PRASUGREL HYDROBROMIDE AND PROCESS FOR PREPARING THE SAME
CZ2009762A3 (cs) * 2009-11-16 2011-05-25 Zentiva, K. S. Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby
CZ2009763A3 (cs) * 2009-11-16 2011-05-25 Zentiva, K. S. Zpusob výroby vysoce cistého 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a jeho nových farmaceuticky prijatelných solí.
KR20120052381A (ko) 2010-04-08 2012-05-23 테바 파마슈티컬 인더스트리즈 리미티드 프라수그렐 염의 결정형
CN101899056A (zh) 2010-08-02 2010-12-01 江苏万全特创医药生物技术有限公司 普拉格雷氢溴酸盐多晶型物及其制备方法
CN101919823A (zh) * 2010-08-02 2010-12-22 北京德众万全医药科技有限公司 一种治疗血栓的药用组合物

Also Published As

Publication number Publication date
CN102656175B (zh) 2015-08-26
KR20150140871A (ko) 2015-12-16
ES2533681T3 (es) 2015-04-14
EP2448945B1 (en) 2015-01-07
US9012641B2 (en) 2015-04-21
JP2013523837A (ja) 2013-06-17
PL2448945T3 (pl) 2015-06-30
CN102656175A (zh) 2012-09-05
US20140336217A1 (en) 2014-11-13
EP2448945A1 (en) 2012-05-09
WO2011127300A1 (en) 2011-10-13
KR20120052381A (ko) 2012-05-23
JP5730986B2 (ja) 2015-06-10
US20130085154A1 (en) 2013-04-04
KR20140110096A (ko) 2014-09-16
EP2883877A1 (en) 2015-06-17
KR101785186B1 (ko) 2017-10-12
HRP20150356T1 (hr) 2015-05-08
PT2448945E (pt) 2015-04-09
JP2015096553A (ja) 2015-05-21
US8802854B2 (en) 2014-08-12

Similar Documents

Publication Publication Date Title
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
HK1244183A1 (zh) Ivacaftor的氘化衍生物
IL226489B (en) Salts and crystalline forms of a substance that promotes programmed cell death
EP2742051A4 (en) AMORPHIC FORM OF DOLUTEGRAVIR
SG10201500451TA (en) Crystalline forms of a purine derivative
HUE047354T2 (hu) Ivacaftor deuterizált származékai
HK1195770A1 (en) Amorphous solid salts of cobicistat (gs-9350) (cobicistat)(gs-9350)
IL215315A0 (en) Solid state forms of sitagliptin salts
PL2448945T3 (pl) Krystaliczne postacie soli prasugrelu
ZA201308160B (en) Crystalline salts of asenapine
PT2571355T (pt) Sal de cloridrato cristalino de darunavir
HK1182383A1 (zh) 激酶抑制劑的結晶形式
HK1200454A1 (zh) 琥珀酸鹽的晶形
IL223584A0 (en) Crystalline form of a 3-phenoxymethylpyrrolidine compounds
PL2714707T3 (pl) Krystalizacja chlorowodorku epirubicyny
IL230977A (en) A crystalline form of relapaldib
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
HK1182384A1 (en) Crystalline forms of kinase inhibitors
HK1179255A1 (en) Crystalline forms of kinase inhibitors
IL231452A (en) An amorphous form of a dolotgrave